Revance Therapeutics (NASDAQ: RVNC)

28.08 -0.51 (-1.78%)

Earnings

Quarter		Prior	Estimate	Actual	Surprise
Q3 2021 After-Hours	EPS: REV:	-1.34 3.835M
Q2 2021 After-Hours	EPS: REV:
Q1 2021 After-Hours	EPS: REV:	-1.15 58K
Q4 2020 After-Hours	EPS: REV:	-0.99 89K
Q3 2020 After-Hours	EPS: REV:	-0.96 46K	-1.03 1.78M	-1.34 3.835M	-30.1% 115.45%
Q2 2020 After-Hours	EPS: REV:	-0.86 0	-1.01 450K	-1.12 299K	-10.89% -33.56%
Q1 2020 After-Hours	EPS: REV:	-0.85 278K	-0.90 170K	-1.15 58K	-27.78% -65.88%
Q4 2019 After-Hours	EPS: REV:	-1.12 487K	-0.98 2.29M	-0.99 89K	-1.02% -96.11%
Q3 2019 After-Hours	EPS: REV:	-0.91 2.362M	-0.98 430K	-0.96 46K	2.04% -89.3%
Q2 2019 After-Hours	EPS: REV:	-0.94 686K	-0.91 710K	-0.86 0	5.49% -100%

Quarter		Prior	Estimate	Actual	Surprise
Q3 2021 After-Hours	EPS: REV:	-1.34 3.835M
Q2 2021 After-Hours	EPS: REV:
Q1 2021 After-Hours	EPS: REV:	-1.15 58K
Q4 2020 After-Hours	EPS: REV:	-0.99 89K
Q3 2020 After-Hours	EPS: REV:	-0.96 46K	-1.03 1.78M	-1.34 3.835M	-30.1% 115.45%
Q2 2020 After-Hours	EPS: REV:	-0.86 0	-1.01 450K	-1.12 299K	-10.89% -33.56%
Q1 2020 After-Hours	EPS: REV:	-0.85 278K	-0.90 170K	-1.15 58K	-27.78% -65.88%
Q4 2019 After-Hours	EPS: REV:	-1.12 487K	-0.98 2.29M	-0.99 89K	-1.02% -96.11%
Q3 2019 After-Hours	EPS: REV:	-0.91 2.362M	-0.98 430K	-0.96 46K	2.04% -89.3%
Q2 2019 After-Hours	EPS: REV:	-0.94 686K	-0.91 710K	-0.86 0	5.49% -100%